Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...
Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...
SINGAPORE - Media OutReach Newswire - 22 December 2025 - Pyxis, a leading Singapore-based maritime electrification startup, has secured S$13 million in the first close of its S$18 million growth ...
BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...
Founded in 1956 as Nevada’s first and oldest school of nursing, the Orvis School of Nursing has a proud legacy of educating and empowering nursing leaders. Through rigorous academics, innovative ...
The BSN Pathway is built on a traditional four-year undergraduate curriculum that provides a foundational education that includes both academic and professional nursing courses essential for clinical ...
Pyxis Tankers Inc. operates as a maritime transportation company with a focus on the tanker and dry-bulk sectors in the United States and internationally. It operates through two segments: Tanker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback